Aytu Biopharma (AYTU) Receivables - Other (2021)

Aytu Biopharma (AYTU) reported Receivables - Other of $9000.0 for Q3 2021, down 57.14% quarter-over-quarter from $21000.0 in Q2 2021.

Aytu Biopharma (AYTU) Receivables - Other (2021) Analysis & Trends

Aytu Biopharma (AYTU) has 1 years of Receivables - Other data on file, last reported at $9000.0 in Q3 2021.

Receivables - Other for Q3 2021 came in at $9000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $9000.0 (changed N/A YoY), and the FY2021 annual result was $21000.0, changed N/A from the prior year.
Receivables - Other declined to $9000.0 in Q3 2021 per AYTU's latest filing, from $21000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $21000.0 in Q2 2021 and troughed at $9000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Aytu Biopharma	24.60 Mn	-2.12 Mn	7.60 Mn

Download Data